Tevogen Bio Holdings Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tevogen Bio Holdings Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($5.73M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.50M) | Aug 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($5.50M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($10.37M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.37M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($10.37M) | Nov 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.88M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($9.66M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($9.66M) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | $11.26M | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | $11.26M | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | $11.26M | Nov 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.90M) | Nov 19, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($22.18M) | Aug 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($22.18M) | Nov 19, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($30.76M) | Nov 19, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($30.76M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($30.76M) | May 28, 2024 |
| Q3 | 2023 | Sep 30, 2022 | $1.61M | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | $207.0K | Aug 21, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($5.73M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.44M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.36M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($6.09M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.60M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($29.52M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($2.33M) | Nov 19, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($2.18M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($2.32M) | May 28, 2024 |